Dupuytren’s Contracture Market Research Report- Global Forecast till 2027

Dupuytren’s Contracture Market Information: By Types (Type I, Type II, Type III) By Diagnosis (Physical Examination, X-Ray, others) By Surgery (Needle Aponeurotomy (NA), others), Drug (Steroids, Collagenase Injection, others) By Therapy, and By End User - Global Forecast till 2027

ID: MRFR/Pharma/2992-HCR | February 2021 | Region: Global | 80 pages

Dupuytren’s contracture Market Overview
Dupuytren's contracture is a condition in which there is difficulty in articulating fingers due to formation of tissue knots under the skin. In severe conditions, the fingers become permanently bent in a flexed position. Dupuytren's contracture is typically not painful and generally affects the ring finger followed by the little and middle fingers. The exact causes of Dupuytren's contracture are unknown, however, the risk factors include alcoholism, smoking, thyroid problems, liver disease, diabetes, previous hand trauma, epilepsy, family history etc. Dupuytren's contracture has a higher rate in males over the age of 50. There is also a genetic propensity with Caucasians being affected more while it is rare among Asians and Africans. Dupuytren's contracture has a regress rate of approximately 10% of patients. The less severe forms of the disease are treated with steroid treatment and physiotherapy while surgery is usually performed when the metacarpophalangeal joint contracture exceeds 40 degrees or when the proximal interphalangeal joint contracture exceeds 20 degrees.


The annual incidence proportion was estimated at about 3 cases per 10,000 adults. The occurrence rate of this condition in the United States is about 5% of people, while Scandinavian nations have a higher rate of about 30% of men over 60 years old having the condition. 


The market drivers for Dupuytren’s contracture market are, increase in risk factors rising incomes, growing screening, increasing geriatric population etc. The market restraints are cost of Dupuytren’s contracture surgery, complications and risk of the surgery, invasive nature of treatment, and regression of the disease even after treatment etc.


The global Dupuytren’s contracture market is expected to reach USD 5.5 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.


Research Methodology: Dupuytren’s Contracture Market


Sources: Mayo Clinic, Healthline Media, MRFR Analysis


Intended Audience



  • Global Dupuytren’s contracture treatment manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities


Figure 1          Global Dupuytren’s Contracture Market by Surgery, 2016 (%) Dupuytren’s Contracture Market-


Segments: The global dupuytren’s contracture market has been segmented on the basis of types, diagnosis, surgery, drugs, therapy and end users.


Based on type, the market has been segmented as type I, type II, type III.


Based on diagnosis, the market has been segmented as physical examination, x-ray and others.


Based on drug, the market has been segmented as steroids, collagenase injection, immune-modulators, and others.


Based on therapy, the market has been segmented as radiation therapy, physiotherapy and others.


Based on the end user, the market has been segmented as hospitals & clinics, academic and research and others.


Regional analysis: Europe accounted for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the greater prevalence of Dupuytren’s contracture in Europe drives the Dupuytren’s contracture market. Also, concentration of major research companies in the developed countries of this region is adding fuel to the market growth. The highly developed healthcare system of the Scandinavian countries coupled with high expenditure on healthcare, cruises the sale of Dupuytren’s contracture treatment. Europe is led by countries such as Germany and France with Norway, expected to be the fastest growing market.


US is the second largest market in the world due to high income and healthcare penetration. The presence of large healthcare players in the US benefits the market coupled with the high public expenditure on healthcare which comes to be approximately 16 % of the GDP. Asia Pacific region is expected to grow at a slower rate with China and India are likely to lead this market due to fast growing healthcare sector during the forecast period. The lower prevalence of Dupuytren’s contracture in the Asian populations acts as a drag on the market.


Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The development of large hospitals such as the King Fahd hospital in Riyadh is driving the market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development. Also, the lower prevalence of Dupuytren’s contracture in the Asian populations acts as a drag on the market.


Key Players in the Global Dupuytren’s contracture Market Some of key players profiled in the report are Bristol-Meyers Squibb Co., Fresenius Kabi AG, Merck Sharp & Dohme Corp., Pfizer Inc., West-Ward Pharmaceuticals, Spear Pharmacueticals, Actiza Pharmaceutical Private Limited, Nantong Jinghua Pharmaceutical Co., Ltd., Endo International plc., and others.


 


 



Table of Contents

1. Introduction

1.1 Definition

1.2 Scope of Study

1.2.1 Research Objective

1.2.2 Assumptions & Limitations

1.2.2.1 Assumptions

1.2.2.2 Limitations

1.3 Market Structure

2. Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3. Market dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Macroeconomic Indicators

4. Market factor analysis

4.1 Porters Five Forces Model

4.2 Value Chain Analysis

4.3 Pricing Analysis

4.4 Investment Opportunity Analysis

5. Global Dupuytren’s Contracture Market, by Types

5.1 Introduction

5.2 Type I

5.3 Type II

5.4 Type III

6. Global Dupuytren’s Contracture Market, by Diagnosis

6.1 Introduction

6.2 Physical Examination,

6.3 X-Ray

6.4 Others

7. Global Dupuytren’s Contracture Market, by Surgery

7.1 Introduction

7.2 Needle Aponeurotomy (NA)

7.4 Open Hand Surgery

7.5 Fasciectomy

7.6 Dermofasciectomy

7.7 Others

8. Global Dupuytren’s Contracture Market, by Drugs

8.1 Introduction

8.2 Steroids

8.3 Collagenase Injection

8.4 Immune-Modulators

8.5 Others

9. Global Dupuytren’s Contracture Market, by Therapy

9.1 Introduction

9.2 Radiation Therapy

9.3 Physiotherapy

9.4 Others

10. Global Dupuytren’s Contracture Market, by End Users

10.1 Introduction

10.2 Hospitals & Clinics

10.3 Academic and Research

10.4 Others

11. Global Dupuytren’s Contracture Market, by Region

11.1 America s

11.1.1 North America

11.1.1.1 US

11.1.1.2 Canada

11.1.2 South America

11.2 Europe

11.2.1 Western Europe

11.2.1.1 Germany

11.2.1.2 France

11.2.1.3 UK

11.2.1.4 Italy

11.2.1.5 Spain

11.2.1.6 Rest of Western Europe

11.2.2 Eastern Europe

11.3 Asia Pacific

11.3.1 Japan

11.3.2 China

11.3.3 India

11.3.4 Australia

11.3.5 Republic of Korea

11.3.6 Rest of Asia Pacific

11.4 Middle East & Africa

11.4.1 Saudi Arabia

11.4.2 UAE

11.4.3 Egypt

11.4.4 South Africa

11.4.5 Rest of Middle East and Africa

12. Competitive landscape

12.1 Major Strategies Adopted by Market Players

12.1.1 Strategic Partnership

12.1.2 Merger & Acquisition

13. Company profile

13.1 Bristol-Meyers Squibb Co.

13.1.1 Overview

13.1.2 Product Overview

13.1.3 Financials

13.1.4 Key Developments

13.2 Fresenius Kabi AG

13.2.1 Overview

13.2.2 Product Overview

13.2.3 Financials

13.2.4 Key Developments

13.3 Merck Sharp & Dohme Corp.

13.3.1 Overview

13.3.2 Product Overview

13.3.3 Financials

13.3.4 Key Development

13.4 Pfizer Inc.

13.4.1 Overview

13.4.2 Product Overview

13.4.3 Financials

13.4.4 Key Development

13.5 West-Ward Pharmaceuticals Corp.

13.5.1 Overview

13.5.2 Product Overview

13.5.3 Financials

13.5.4 Key Development

13.6 Spear Pharmacueticals

13.6.1 Overview

13.6.2 Product Overview

13.6.3 Financials

13.6.4 Key Development

13.7 Actiza Pharmaceutical Private Limited

13.7.1 Overview

13.7.2 Product Overview

13.7.3 Financials

13.7.4 Key Development

13.8 Nantong Jinghua Pharmaceutical Co., Ltd.

13.8.1 Overview

13.8.2 Product Overview

13.8.3 Financials

13.8.4 Key Development

13.9 Endo International plc.

13.9.1 Overview

13.9.2 Product Overview

13.9.3 Financials

13.9.4 Key Development

13.13 Others

13.13.1 Overview

13.13.2 Product Overview

13.13.3 Financials

13.13.4 Key Development

14. Conclusion

14.1 Key Findings

14.1.1 From CEO’s Viewpoint

14.1.2 Unmet Needs of The Market

14.2 Key Companies to Watch

14.3 Prediction of Dupuytren’s Contracture Treatment Industry

15. Appendix

List of Tables

TABLE 1 GLOBAL DUPUYTREN’S CONTRACTURE MARKET, BY TYPES, 2020-2027 (USD MILLION)

TABLE 2 TYPE I FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 3 TYPE II FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 4 TYPE III FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 5 GLOBAL DUPUYTREN’S CONTRACTURE MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 6 PHYSICAL EXAMINATION FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 7 X-RAY FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 8 OTHERS FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 9 GLOBAL DUPUYTREN’S CONTRACTURE MARKET, BY SURGERIES, 2020-2027 (USD MILLION)

TABLE 10 NEEDLE APONEUROTOMY (NA) FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 11 OPEN HAND SURGERY FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 12 FASCIECTOMY FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 13 DERMOFASCIECTOMY FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 14 OTHERS FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 15 GLOBAL DUPUYTREN’S CONTRACTURE MARKET, BY DRUGS, 2020-2027 (USD MILLION)

TABLE 16 STEROIDS FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 17 COLLAGENASE INJECTION FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 18 IMMUNE-MODULATORSFOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 19 OTHERS FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 20 GLOBAL DUPUYTREN’S CONTRACTURE MARKET, BY THERAPY, 2020-2027 (USD MILLION)

TABLE 21 RADIATION THERAPY FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 22 PHYSIOTHERAPY FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 23 PHYSIOTHERAPY FOR DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 24 GLOBAL DUPUYTREN’S CONTRACTURE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 25 NORTH AMERICA DUPUYTREN’S CONTRACTURE MARKET, BY COUNTRY 2020-2027 (USD MILLION)

TABLE 26 NORTH AMERICA DUPUYTREN’S CONTRACTURE MARKET, BY TYPE 2020-2027 (USD MILLION)

TABLE 27 NORTH AMERICA DUPUYTREN’S CONTRACTURE MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

TABLE 28 NORTH AMERICA DUPUYTREN’S CONTRACTURE MARKET, BY SURGERIES, 2020-2027 (USD MILLION)

TABLE 29 NORTH AMERICA DUPUYTREN’S CONTRACTURE MARKET, BY DRUGS, 2020-2027 (USD MILLION)

TABLE 30 NORTH AMERICA DUPUYTREN’S CONTRACTURE MARKET, BY THERAPY, 2020-2027 (USD MILLION)

TABLE 31 NORTH AMERICA DUPUYTREN’S CONTRACTURE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 32 NORTH AMERICA DUPUYTREN’S CONTRACTURE MARKET BY REGION 2020-2027 (USD MILLION

TABLE 33 EUROPE DUPUYTREN’S CONTRACTURE MARKET BY COUNTRY 2020-2027 (USD MILLION)

TABLE 34 EUROPE DUPUYTREN’S CONTRACTURE MARKET, BY TYPE 2020-2027 (USD MILLION)

TABLE 35 EUROPE BIOLOGICAL THERAPY MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

TABLE 36 EUROPE DUPUYTREN’S CONTRACTURE MARKET, BY, SURGERY 2020-2027 (USD MILLION) TABLE

TABLE 37 EUROPE DUPUYTREN’S CONTRACTURE MARKET, BY DRUGS, 2020-2027 (USD MILLION)

TABLE 38 EUROPE DUPUYTREN’S CONTRACTURE MARKET, BY THERAPY, 2020-2027 (USD MILLION)

TABLE 39 EUROPE DUPUYTREN’S CONTRACTURE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 40 EUROPE DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 41 ASIA PACIFIC DUPUYTREN’S CONTRACTURE MARKET BY COUNTRY 2020-2027 (USD MILLION)

TABLE 42 ASIA PACIFIC DUPUYTREN’S CONTRACTURE MARKET, BY TYPE 2020-2027 (USD MILLION)

TABLE 43 ASIA PACIFIC BIOLOGICAL THERAPY MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

TABLE 44 ASIA PACIFIC DUPUYTREN’S CONTRACTURE MARKET, BY, SURGERY 2020-2027 (USD MILLION) TABLE

TABLE 45 ASIA PACIFIC DUPUYTREN’S CONTRACTURE MARKET, BY DRUGS, 2020-2027 (USD MILLION)

TABLE 46 ASIA PACIFIC DUPUYTREN’S CONTRACTURE MARKET, BY THERAPY, 2020-2027 (USD MILLION)

TABLE 47 ASIA PACIFIC DUPUYTREN’S CONTRACTURE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 48 ASIA PACIFIC DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA DUPUYTREN’S CONTRACTURE MARKET BY COUNTRY 2020-2027 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA DUPUYTREN’S CONTRACTURE MARKET, BY TYPE 2020-2027 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA BIOLOGICAL THERAPY MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

TABLE 53 MIDDLE EAST & AFRICA DUPUYTREN’S CONTRACTURE MARKET, BY, SURGERY 2020-2027 (USD MILLION) TABLE

TABLE 54 MIDDLE EAST & AFRICA DUPUYTREN’S CONTRACTURE MARKET, BY DRUGS, 2020-2027 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA DUPUYTREN’S CONTRACTURE MARKET, BY THERAPY, 2020-2027 (USD MILLION)

TABLE 56 EUROPE DUPUYTREN’S CONTRACTURE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 57 EUROPE DUPUYTREN’S CONTRACTURE MARKET, BY REGION 2020-2027 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET DYNAMICS FOR GLOBAL DUPUYTREN’S CONTRACTURE MARKET

FIGURE 3 GLOBAL DUPUYTREN’S CONTRACTURE MAKRET, BY SEGMENT, 2020

FIGURE 4 GLOBAL DUPUYTREN’S CONTRACTURE SUCCESS MARKET, BY REGION

FIGURE 5 GLOBAL DUPUYTREN’S CONTRACTURE MARKET SHARE, BY TYPE 2020

FIGURE 6 GLOBAL DUPUYTREN’S CONTRACTURE MARKET SHARE, BY DIAGNOSIS, 2020

FIGURE 7 GLOBAL DUPUYTREN’S CONTRACTURE MARKET SHARE, BY SURGERY, 2020

FIGURE 8 GLOBAL DUPUYTREN’S CONTRACTURE MARKET SHARE, BY DRUGS, 2020

FIGURE 9 GLOBAL DUPUYTREN’S CONTRACTURE MARKET SHARE, BY THERAPY, 2020

FIGURE 10 GLOBAL DUPUYTREN’S CONTRACTURE MARKET SHARE, BY END USER, 2020

FIGURE 11 GLOBAL DUPUYTREN’S CONTRACTURE MARKET SHARE, 2020

FIGURE 12 GLOBAL DUPUYTREN’S CONTRACTURE MARKET SHARE, BY REGION, 2020

FIGURE 13 NORTH AMERICA DUPUYTREN’S CONTRACTURE MARKET SHARE, BY COUNTRY, 2020

FIGURE 14 EUROPE DUPUYTREN’S CONTRACTURE MARKET SHARE, BY COUNTRY, 2020

FIGURE 15 ASIA PACIFIC DUPUYTREN’S CONTRACTURE MARKET SHARE, BY COUNTRY, 2020

FIGURE 16 MIDDLE EAST & AFRICA DUPUYTREN’S CONTRACTURE MARKET, BY REGION, 2020

FIGURE 17 GLOBAL DUPUYTREN’S CONTRACTURE MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 18 BRISTOL-MEYERS SQUIBB CO. KEY FINANCIALS

FIGURE 19 BRISTOL-MEYERS SQUIBB CO.: SEGMENTAL REVENUE

FIGURE 20 BRISTOL-MEYERS SQUIBB CO.: GEOGRAPHICAL REVENUE

FIGURE 21 FRESENIUS KABI AG: KEY FINANCIALS

FIGURE 22 FRESENIUS KABI AG: SEGMENTAL REVENUE

FIGURE 23 FRESENIUS KABI AG: GEOGRAPHICAL REVENUE

FIGURE 24 MERCK SHARP & DOHME CORP.: KEY FINANCIALS

FIGURE 25 MERCK SHARP & DOHME CORP.: SEGMENTAL REVENUE

FIGURE 26 MERCK SHARP & DOHME CORP.: GEOGRAPHICAL REVENUE

FIGURE 27 PFIZER INC.: KEY FINANCIALS

FIGURE 28 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 29 PFIZER INC.: GEOGRAPHICAL REVENUE

FIGURE 30 WEST-WARD PHARMACEUTICALS CORP.: FINANCIAL REVENUE

FIGURE 31 WEST-WARD PHARMACEUTICALS CORP.: SEGMENTAL REVENUE

FIGURE 32 WEST-WARD PHARMACEUTICALS CORP.: GEOGRPAHICAL REVENUE

FIGURE 33 SPEAR PHARMACUETICALS: FINANCIAL REVENUE

FIGURE 34 SPEAR PHARMACUETICALS: SEGMENTAL REVENUE

FIGURE 35 SPEAR PHARMACUETICALS: GEOGRPAHICAL REVENUE